Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2022 08:00 ET | Source: BioVie, Inc.

BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
October 19, 2022 06:00 ET | Source: BioVie, Inc.

BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

CARSON CITY, Nev., Oct. 19, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of...
October 04, 2022 08:00 ET | Source: BioVie, Inc.

BioVie Issues Letter to Shareholders

Positive preliminary data from investigator-sponsored Phase 2 Alzheimer’s trial show high proportion of responders and level of cognitive improvements seen for NE3107 confirm NE3107’s status as one of...
September 29, 2022 08:00 ET | Source: BioVie, Inc.

BioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference

RENO, Nev., Sept. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
September 07, 2022 06:00 ET | Source: BioVie, Inc.

BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease

Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient’s daily abilities) with NE3107 treatment (p<0.0001 to p<0.05).NE3107 is...
June 23, 2022 08:00 ET | Source: BioVie, Inc.

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
April 25, 2022 08:00 ET | Source: BioVie, Inc.

BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference

CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of...
March 10, 2022 08:00 ET | Source: BioVie, Inc.

BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and...
March 09, 2022 16:05 ET | Source: BioVie, Inc.

BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced...
January 20, 2022 08:00 ET | Source: BioVie, Inc.

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced...